It will be inevitable that not all cells will respond to differen- enhanced efficacy in the treatment of certain disorders.
Introduction production of granulocytes, macrophages and also eosinophils from bone marrow cells in soft agar cultures. 17 It also Since the findings that the intracellular vitamin D receptor plays a role in influencing the functional activity of mature (VDR) is expressed in myeloid cells, 1, 2 it has been recognised leukocytes, mediating their immune responses accordingly. 18 that its ligand, 1␣, 25-dihydroxyvitamin D 3 (1,25(OH) 2 D 3 ), is There have been previous reports demonstrating synergistic able to regulate myeloid cell replication and differentiation.
effects of 1,25(OH) 2 D 3 and GM-CSF in the differentiation of This role would be in addition to that normally associated the human monocytic leukaemia cell line, U937. 19, 20 In the with 1,25(OH) 2 D 3 , namely the maintenance of calcium present study we have used the U937 and the human myelohomeostasis by its actions on intestine, bone and kidney. The monocytic HL-60 cell lines to compare the differentiative binding of 1,25(OH) 2 D 3 to its receptor modulates transcription properties of 1,25(OH) 2 D 3 , EB1089 and KH1060, and also to of vitamin D responsive genes, and subsequent expression of evaluate their interactions with GM-CSF. bioactive proteins, acting to regulate the functions of target cells. 3 The effects of 1,25(OH) 2 D 3 on immune cell function have Materials and methods been well documented. [4] [5] [6] [7] [8] Studies in vitro have shown that human myeloid cells can be induced by 1,25(OH) 2 grams were generated (logE-01 scale), with cursors being set 2 mM glutamine, 100 U/ml penicillin, 100 g/ml streptomycin to ensure that cells incubated with isotypic control antibodies and 10% foetal calf serum (GlobePharm, Esher, UK). To estabwere not more than 2% non-specifically stained. Data sets lish the ability of the vitamin D derivatives to bind to VDR, were recorded in real time, gating cells according to their sideligand binding assays were performed. VDR was extracted angle light scatter and fluorescence channel intensities. from untreated U937 and HL-60 cell cultures with a hyperResults for these studies have been recorded as the mean flutonic buffer containing 0.3 M KCl, 10 mM Tris-HCl, 1 mM orescence index, which is the product of the % fluorescence EDTA, 10 mM sodium molybdate, 4 mM dithiothreitol, pH 7.4, and the mean fluorescence intensity, with 20 000 cells being with 500 trypsin inhibitor units trasylol/ml. The cells were soncounted per treatment. icated, and high speed supernatants prepared. Aliquots of the resulting VDR cytosols were incubated with 0.05 Ci (10 000 dpm) 3 H-1,25(OH) 2 D 3 , in the presence or absence of increas-
Statistical methods
ing amounts of radioinert vitamin D compound, for 18 h at 4°C. Bound from free sterols were separated by the Comparisons were made using the unpaired Student's t-test or hydroxylapatite method previously described, 21 with radioby three-way analysis of variance. activity being detected by liquid scintillation counting.
Results

Cell proliferation and differentiation studies
The structures of 1,25(OH) 2 D 3 , EB1089 and KH1060 are shown in Figure 1 . Assessment of leukaemic cell proliferation was determined by cell counts. U937 and HL-60 cells were seeded at 2 × 10 
Cell morphology
To analyse changes in U937 and HL-60 cell morphology following treatment with the differentiation agents, cells were harvested and cytocentrifuged onto microscope slides. The slides were fixed and subjected to Wright-Geimsa staining before microscopic examination.
and HL-60 cell cultures, as shown in Figure 2 . The compe-( Figure 3) . A dose-related inhibition of cell proliferation was observed in both cell lines, with EB1089 and KH1060 exhibittition curves for EB1089 and KH1060 were displaced to the right of the curve for 1,25(OH) 2 EB1089 and KH1060 were co-incubated with GM-CSF, compared to the activity of the vitamin D derivatives or GM-CSF a dose-dependent manner following 96 h treatment. Notably, at the concentration of 5 × 10 −10 M, EB1089 and KH1060 were alone. A three-fold induction of cell differentiation was observed with 1,25(OH) 2 D 3 /GM-CSF, and a four-fold inducfour-and seven-fold more potent than 1,25(OH) 2 D 3 in their differentiative activity in the U937 cell line, and 12-and 16-tion with EB1089/GM-CSF and KH1060/GM-CSF. The U937 cells appeared to be nonresponsive to GM-CSF, indicated by fold more potent that the parent hormone in the HL-60 cell line.
low NBT reduction. In contrast, the cotreatment of the vitamin D compounds with GM-CSF in the HL-60 cells did not show any enhancement in the differentiation of these cells. Figure 6 illustrates the effects of EB1089 on U937 cell mor-
Induction of leukaemic cell differentiation by vitamin D derivatives and GM-CSF
phology following 48 h treatment alone or in combination with GM-CSF. Striking changes in cell morphology were observed with cells exposed to the vitamin D analogue on Promotion of U937 and HL-60 cell differentiation by 1,25(OH) 2 D 3 and the analogues was further investigated by its own and in the presence of GM-CSF (Figures 6b and d,  respectively) , including an increase in the cytoplasmic comassessing whether GM-CSF, in the presence of these compounds would be capable of modulating their differentiative partment, the appearance of lysosomal granules and distortion of the cell membrane, characteristic of monocytes/ properties. Figure 5 
Induction by the vitamin D derivatives of cell surface antigens
In order to establish the phenotypic maturation of these leukaemic cell lines by the vitamin D compounds, cell surface antigen expression was measured using FACS analysis. Tables 1 and 2 −10 M of EB1089 or KH1060 significantly increased CD14 antigen expression above control levels, and with enhanced efficacy relative to the native hormone at both time-points. EB1089 increased CD14 expression in U937 cells at 48 h 330-fold, and in HL-60 cells 50-fold compared to 1,25(OH) 2 D 3 . At the same 48 h time-point, KH1060 stimulated over a 600-fold increase in CD14 expression in U937 cells, and an 80-fold increase in HL-60 cells, and thus confirm the potent differentiative properties that these compounds possess. In contrast, 48 h and 96 h treatment with 1 ng/ml GM-CSF revealed that it was a poor inducer of CD14 under these conditions.
The actions of the vitamin D derivatives on the expression of the ␤ 2 -integrin CD11b/18 cell adhesion molecule was examined. Their expression is not monocyte specific although their presence on cell surfaces is indicative of cell maturity. CD11b was constitutively expressed in the uninduced U937 cells. In the presence of the vitamin D derivatives, increases in CD11b antigen expression were observed in both cell lines, with enhanced induction by EB1089 and KH1060. In particular, KH1060 increased CD11b antigen expression in the HL-60 cells by three-fold after 48 h and four-fold following 96 h treatment relative to the control cells, whilst in U937 cell cultures, CD11b was increased four-fold and nine-fold at 48 h and 96 h respectively compared to control cultures. At 1 ng/ml, GM-CSF was ineffective at inducing CD11b above basal levels. A four-fold induction of CD18 relative to control U937 cells was apparent with KH1060 treatment at 48 h, which was increased to an eight-fold induction by 96 h. GM-CSF significantly induced expression of CD18 in the U937 cell line (P Ͻ 0.05), but had no effect at inducing these antigens in the HL-60 cells.
Analysis of cell surface antigen expression also revealed that U937 cells, treated in combination with 5 × 10 −10 M of the vitamin D derivatives and 1 ng/ml GM-CSF, markedly increased the induction of CD14 (Figure 7) . A 30-fold increase of CD14 in U937 cells was apparent following 96 h treatment with 1,25(OH) 2 D 3 /GM-CSF compared to 1,25(OH) 2 D 3 alone, whilst cotreatment with EB1089 or KH1060 and GM-CSF promoted a four-fold induction relative to the actions of each vit- cell cultures after 48 h and 96 h respectively, when compared to untreated cultures ( Table 1) . Treatment of HL-60 cells with these cells, and promotes their differentiation along the monocyte/macrophage lineage. As a consequence of the GM-CSF induced a three-fold increase in CD14 at 48 h and a two-fold increase at 96 h treatment relative to control levdevelopment of hypercalcaemia which accompanies the clinical use of 1,25(OH) 2 D 3 , 12 vitamin D analogues have been els (Table 2) .
Expression of CD11b was enhanced by 1,25(OH) 2 D 3 and synthesised which have reduced calcaemic side-effects, whilst retaining the ability to control cell proliferation and differenthe analogues, in the presence of GM-CSF, in both cell lines (Figure 8 ). EB1089/GM-CSF and KH1060/GM-CSF respecttiation.
We have evaluated the ability of two novel vitamin D anaively were capable of inducing CD11b in U937 cells by fourfold and six-fold at 48 h, and promoting further induction to logues, EB1089 and KH1060, to induce differentiation in U937 and HL-60 cell cultures. In comparison to the native 12-fold and 15-fold at 96 h relative to untreated cultures. In HL-60 cell cultures, EB1089/GM-CSF and KH1060/GM-CSF hormone, EB1089 and KH1060 are at least 10-fold more potent at promoting U937 and HL-60 cell differentiation, as each maintained a five-fold increased induction of CD11b at 96 h compared to control levels. Similar augmentation of assessed by NBT reduction. Phenotypic studies by FACS analysis revealed that expression of CD14 was more readily CD18 expression was observed in both cell lines with combination of the vitamin D derivatives and GM-CSF (data not induced by the analogues in both cell lines relative to 1,25(OH) 2 D 3 . This indicates that EB1089 and KH1060 influshown).
ence maturation of these cells via the monocyte/macrophage pathway. Treatment of cell cultures with GM-CSF revealed that it was a poor inducer of CD14.
Discussion
The ␤ 2 -integrins CD11b and CD18 are cell adhesion molecules (CAMS) found on leukocytes, binding to ligands on The human leukaemia cell lines, U937 and HL-60, have been widely used as in vitro models to study the differential effects other cells or in the extracellular matrix. Relating to immune cells, the ␤ 2 -integrins can promote leukocyte adherence to on their maturity by a variety of differentiation agents. 22 One of these agents, 1,25(OH) 2 D 3 , inhibits the proliferation of endothelial cells and also their migration to inflammatory sites. 23 The vitamin D analogues were also capable of inducing the expression of the ␤ 2 -integrins. GM-CSF alone induced CD18 in U937 cell cultures but was ineffective at inducing CD11b in U937 and HL-60 cells. Thus it would seem that these vitamin D compounds may play a role in regulating the expression of these and similar related CAMS.
Independent reports have shown that 1,25(OH) 2 D 3 , in combination with GM-CSF, can induce synergistic effects on U937 cell differentiation. 19, 20 We have confirmed this observation in our studies, and in addition have noticed similar co-operative effects with the vitamin D analogues in the presence of GM-CSF, using NBT reduction and FACS analysis as indices of cell differentiation. No co-operative effects on HL-60 cell differentiation were observed with cotreatment of 5 × 10 −9 M of the vitamin D compounds and 1 ng/ml GM-CSF by NBT reduction. However, FACS analysis revealed enhanced effects on CD14 and CD11b antigen expression with the lower dose of 5 × 10 −10 M of the vitamin D compounds together with GM-CSF. It would seem that the concentration of 5 × 10 −10 M of KH1060 may be capable of terminally differentiating the HL-60 cells, such that only a modest augmentation of CD14 and activity; this may be explained in demonstrations by others that U937 cells express low levels of GM-CSF receptors. 24 The receptor for GM-CSF is comprised of two subunits, an 80 kDa protein with low affinity binding for GM-CSF, and a 120 kDa protein, which also has sequence homology with the IL-3 receptor. The complex of these subunits yields a high affinity GM-CSF receptor which confers biological activity. 25, 26 Ligand binding assays performed in our laboratories have indicated that GM-CSF does not modulate U937 VDR concentration (data not shown). A possible mechanism of action regarding the augmentation of leukaemia cell differentiation by the vitamin D derivatives and GM-CSF may therefore be the transcription of vitamin D responsive genes following the binding of VDR by its ligand, which ultimately promotes the expression of GM-CSF receptors. On binding, the GM-CSFreceptor complex may then be internalised by the cell, as previously described elsewhere. 27 Events taking place following internalisation and eliciting cellular effects are not well understood, but several reports have described various processes such as activation of protein kinase C (PK-C) mechanisms, 28 stimulation of tyrosine residue protein phosphorylation, 29, 30 increases in the expression of the immediate-early response gene, c-jun mRNA and activation of the transcription factor complex, activator protein-1 (AP-1). 28 The protein products of c-jun, and another immediate-early response gene c-fos, heterodimerise to form AP-1 complexes, and are important in DNA transcription. Cellular responses to 1,25(OH) 2 D 3 include the regulation of PK-C mRNA in HL-60 cells. 31 Induction of c-fos mRNA expression by 1,25(OH) 2 D 3 was found to be augmented with GM-CSF cotreatment in U937 cells, 20 and a 
